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Abstract: Dofetilide (UK 68,798), a new
antiarrhythmic agent, blocks potassium
channels selectively and acts primarily by
prolonging repolarization duration. The aim
of this study was to investigate ratedependent repolarization changes due to
dofetilide in a fast beating in-vitro heart
model.
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The study was designed using Langendorff
perfusion of rabbit hearts at the drug
concentrations of 1 nM, 3 nM and 10 nM. The
electrophysiological
evaluations
were
performed using the recording of epicardial
monophasic action potentials. Atrial pacing
was set at the cycle length (ms) of 300, 325,
350, 375 and 400 so that repolarization
duration could be measured in different heart
rates. The study also focused on the
interventricular repolarization heterogeneity
between the right and left epicardial regions.

Introduction
Dofetilide (UK 68,798) is a selective potassium
channel blocker which inhibits the fast component of the
delayed rectifying K+ current (1,2) and acts primarily by
prolonging repolarization duration as demonstrated in invitro preparations (3-6) in animal experiments (7,8) and
in human studies (9-12). Previous investigations have
shown that the dofetilide-induced prolongation of
repolarization duration was prominent at longer cycle
lengths (1,3-7,11,12). This phenomenon termed
reverse-rate dependency in repolarization duration may
induces proarrhythmia such as torsade de pointes (13).
Proarrhythmias may also be correlated with the
increase in dispersion of the action potential duration, and
the heterogeneity of repolarization duration in various
regions of the heart (14-16). Different models have been
used to assess the changes in repolarization dispersion

Dofetilide prolonged monophasic action
potential duration at 90 % of repolarization
on both sides of the epicardium in a
concentration- and reverse-rate-dependent
manner. However, the rate-dependent
prolongation of action potential duration due
to dofetilide was not accompanied by
increased interventricular dispersion of
repolarization. No proarrhythmia due to
dofetilide was seen in our model. This may be
explained by the rate-dependent stability in
repolarization dispersion. Thus, the presented
model indicated that dofetilide-induced
prolongation of repolarization is not
proarrhythmic in isolated fast beating hearts.

Key Words: Dofetilide, Rate dependency,
Monophasic action potential duration,
Interventricular dispersion, Langendorff
perfusion

due to dofetilide (8-11,17-20). However, there is no
published data about the rate-dependent effects of
dofetilide on repolarization dispersion in isolated fast
beating hearts. It is considered that isolated rabbit hearts
with atrial pacing may be suitable for increasing the heart
rate in our model.
In recent studies, endocardial interventricular
dispersion was reported to depend on heart rate and may
be a relevant factor for the initiation of torsade de pointes
in bradycardia (21,22). With regard to interventricular
dispersion, in-vitro interventricular dispersion of
repolarization was measured here, using the epicardial
action potential recording technique for both sides of the
epicardium. It is of interest to know whether dofetilide
changes epicardial interventricular dispersion in a ratedependent manner.

*Presented in part at the 26th Congress of the Turkish Physiological Society
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Methods

A

Isolated heart preparation
Albino rabbits of either sex, weighing 2000-2800 g,
were killed by cervical dislocation. The chest was quickly
opened and the heart was placed in 50 ml of ice-cold
Tyrode’s solution with heparin immediately after
removal.
The retrograde perfusion of isolated heart began
through the aorta in the Langendorff system using a
modified Thyrode’s solution composed of (in mM) NaCl
129, KCl 4.7, CaCl2 2.0, MgCl2 1.0, NaHCO3 14,
NaH2PO4 1.0 and glucose 12. The perfusion pressure was
adjusted to 75 ± 2 cm H2O for all experiments. The
perfusion solution was indirectly warmed to a constant
temperature of 37 °C, using a pump with water
circulation. The solution was saturated with a mixture of
95 % oxygen and 5 % carbon dioxide. The heart was
freed from the epicardium and peripheral tissue such as
lung and fat tissue. The pH value of the perfusion solution
was monitored during the experiment and kept at 7.40.
Epicardial monophasic action potentials
Figure 1A shows the experimental setup for in-vitro
recording of monophasic action potentials (MAPs). Two
Ag-AgCl bipolar contact electrodes (Franz MAP probe,
electrode spacing 3.5 mm, diameter 4F, EP Technologies
Inc., CA) with holders, and plastic arms were positioned
on the right and left epicardial surface of ventricles. The
electrical continuity between the MAP reference electrode
and the epicardium was provided with a sponge as
described by Franz et al. (23).
The epicardial monophasic action potentials were
preamplified at a filter setting of 0.5-1000 Hz and
displayed on an oscilloscope (Heinemann & Gregori
GmbH, Kelkheim, Germany). A thermosensitive recorder
(Schwarzer Cardioscript CD 6000, Picker, Germany) was
used at a paper speed of 100 mm/s. The amplitude of
MAP was greater than 5 mV and the isoelectric line was
flat. The MAP duration was determined at 90 % of
repolarization. The right and left epicardial monophasic
action potential durations, RMAPD90 and LMAPD90, were
measured using simultaneous recordings. Figure 1B
shows samples of original MAP tracings obtained at
different dofetilide concentrations.
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The experimental setup (A) and examples of monophasic
action potentials during an experiment (B).
A. MAPe: the bipolar contact MAP electrode, Se: a bipolar
stimulation electrode, H: holder for the MAP electrode, F: a
foam rubber sponge, S: an elastic arm which allows the
MAP electrode to move in accordance with the heart
action, AO: the aorta, P: a. pulmonalis, RA: right atrium,
LA: left atrium, RV: right ventricle, LV: left ventricle. B.
Both right and left epicardial monophasic action potentials
(RMAP and LMAP) demonstrate dose-dependent
prolongation of repolarization at a constant cycle length of
375 ms. “0 nM” is the pre-drug condition. Durations at 90
% of repolarization are given in ms for each signal.

Protocol of experiments
The pre-drug perfusion lasted 45 min. After this
baseline, for each experiment the heart was exposed to
dofetilide at concentrations of 1 nM, 3 nM and 10 nM,
respectively. Each period of drug perfusion also lasted 45
min.
The spontaneous beat to beat interval at the
beginning of the experiments was between 403 and 448
ms. A bipolar silver electrode for atrial pacing was
attached to the right atrial appendage and connected to a
programmable stimulator (Model 5325, Medtronic Inc.,
USA). The stimulator generated rectangular pulses with a
duration of 2 ms at twice the diastolic threshold.
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For both pre-drug and post-drug conditions, the heart
was stimulated at cycle lengths (CLs) of 400, 375, 350,
325 and 300 ms, respectively. The stimulation period
lasted 2-3 min for each CL. The average of the last three
MAP signals in a given experimental condition was used
to measure the repolarization duration. In sham
experiments (n = 4), no drug was added to the perfusion,
but the heart rate was altered using the same CL values.
The results of the sham experiments, which are not
presented here, were no different from those of pre-drug
conditions.
Drug preparation
Dofetilide (UK-68,798, Pfizer Central Research, Kent,
England) was dissolved in distilled water acidified by the
addition of a solution of HCL. Thus, a stock solution (pH
3) of 10 mM dofetilide was produced and it was kept at
-18 °C. The stock was diluted with Tyrode's solution to
the desired concentrations of 1 nM, 3 nM and 10 nM on
the day of the experiment.
Data analysis
Data are represented as mean ± SEM. The statistical
comparisons were performed using one-way ANOVA.
Comparison of repolarization duration between the predrug and post-drug period was done by the paired t-test.
Student’s t-tests, non-paired or also paired, were used
for rate-dependent changes in prolongation of
repolarization and for dispersion changes. Significance
was accepted at the 0.05 level of probability.

Table.

Results
The repolarization durations
The monophasic action potential durations for both
the pre- and post-drug conditions are given in the Table.
Firstly, the monophasic action potential duration in the
pre-drug condition depended on the heart rate. The
RMAPD90, which was found to be 153 ± 3 ms at a CL of
300 ms, increased to 172 ± 4 ms at a CL of 400 ms. The
LMAPD90 was 163 ± 4 ms in pre-drug condition at a CL
of 400 ms. This value decreased to 145 ± 3 ms at a CL
of 300 ms.
Secondly, the RMAPD90 and LMAPD90 were prolonged
due to dofetilide concentration. The dofetilide perfusion
even at the lowest concentration (1 nM) causes significant
lengthening of repolarization on both sides of the
epicardium. Exceptionally, at a CL of 325 ms and of 300
ms, the drug-induced prolongation of LMAPD90 due to the
concentration of 1 nM is not statistically significant
(Table).
Dose and rate dependency of dofetilide-induced
repolarization prolongation
Figures 2A and B show dose- and rate-dependent
changes in monophasic action potential duration
(MAPD90). Firstly, for each CL, the difference between the
pre-drug value (0 nM) and post-drug values (1 nM, 3 nM
and 10 nM) was calculated to find the prolongation of
repolarization. Secondly, to assess the rate-dependency
of repolarization prolongation for each drug

Effects of dofetilide on monophasic action potential durations of right epicardium (RMAPD90) and of left epicardium (LMAPD90). The values
are given as mean ± SEM (n = 7). The post-drug durations of monophasic action potential (1 nM, 3 nM, 10 nM) are significantly greater
than the pre-drug duration (0 nM) (* p < 0.05, ** p < 0.01, and *** p < 0.001, with paired t-test). N.S.: non-significant increase.

Cycle Length (ms)

400

375

350

325

300

0 nM

172 ± 4

169 ± 4

165 ± 4

159 ± 3

153 ± 3

1 nM

185 ± 2 **

180 ± 2 **

172 ± 3 *

168 ± 3 **

160 ± 3 **

3 nM

195 ± 4 ***

190 ± 4 ***

183 ± 5 ***

177 ± 4 ***

171 ± 4 ***

10 nM

212 ± 4 ***

206 ± 3 ***

200 ± 2 ***

191 ± 2 ***

182 ± 2 ***

0 nM

163 ± 4

160 ± 4

157 ± 4

152 ± 4

145 ± 3

1 nM

174 ± 3 **

168 ± 4 ***

163 ± 4 *

156 ± 4 (n.s.)

149 ± 5 (n.s.)

3 nM

182 ± 4 ***

178 ± 4 **

174 ± 6 **

169 ± 6 *

161 ± 5 **

10 nM

195 ± 3 ***

189 ± 4 ***

183 ± 4 **

177 ± 4 **

166 ± 4 **

RMAPD90 (ms)

LMAPD90 (ms)
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In the case of 10 nM dofetilide, drug-induced
prolongation at a CL of 400 ms was found to be greater
on both sides of the ventricle in comparison with that of
a CL of 300 ms (p < 0.05, Figures 2A and B). The
reverse-rate-dependency was also found with relatively
lower drug concentrations (1 nM and 3 nM) on the left
ventricle, but not on the right ventricle (p < 0.05). In
other words, reverse-rate- dependent prolongation on
the left side was statistically significant at all the
concentrations tested (1 nM, 3 nM, 10 nM). In contrast,
only a 10 nM concentration caused reverse-ratedependent prolongation of repolarization on the right
ventricle.
Interventricular dispersion of repolarization
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The interventricular dispersion was defined as the
absolute value of the difference between RMAPD90 and
LMAPD90. Figure 3 shows the rate-dependent dispersion
of repolarization duration for both pre-drug (0 nM) and
post-drug conditions. Dofetilide at concentrations of 1
nM and 3 nM did not increase the dispersion of
repolarization compared to those of pre-drugs (0 nM).
Although the dispersion seems to be enhanced by the

10 nM (n.s)

400

Rate-dependent changes in monophasic action potential
duration (MAPD90).
The change means dofetilide-induced prolongation of both
left epicardial MAPD90 (A) and right epicardial MAPD90 (B).
The values at a CL of 300 ms were compared to those at a
CL of 400 ms. * change in MAPD90 is significant (p <
0.05), N.S.: non-significant.
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concentration, the prolongation at a CL of 300 ms was
statistically compared to that at a CL of 400 ms.
The maximum prolongation of RMAPD90 was obtained
with 10 nM dofetilide (Figure 2B). This value was 40.4 ±
4.3 ms at a CL of 400 ms. In contrast, 1 nM dofetilide
prolonged the RMAPD90 only 12.7 ± 2.9 ms at a CL of
400 ms. The maximal change in LMAPD90 after the
application of 10 nM dofetilide was 32.1 ± 3.4 ms at a
CL of 400 ms (Figure 2A). At the same CL, 1 nM dofetile
caused 11.0 ± 1.9 ms prolongation of repolarization on
the left side. As a result, a higher dose of dofetilide
caused greater prolongation of repolarization on both
sides of the epicardium.
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Figure 3.

Pre- and post-drug epicardial interventricular dispersions of
repolarization at different heart rates.
The values at a CL of 300 ms were compared to those at a
CL of 400 ms, for a given concentration. N.S: nonsignificant rate dependency in dispersion (p < 0.05, paired
t-test). In comparison with pre-drug dispersion (0 nM), the
increased dispersion at a concentration of 10 nM is also not
statistically significant (p = 0.064, ANOVA)
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highest concentration of dofetilide (10 nM), this change
was not statistically significant because of greater
standard deviations. In the pre-drug, dispersion was not
dependent on the CL. Similarly, there was no correlation
between the heart rate and interventricular dispersion in
the cases of dofetilide perfusions at concentrations of 1
nM and 3 nM. The interventricular dispersion of
repolarization at the highest concentration (10 nM)
seems to be prominent, but this prominent dispersion
was also not clearly dependent on heart rate.

Discussion
As shown in the Table, dofetilide caused lengthening
in MAP duration even at the lowest concentration (1 nM)
tested. Dofetilide-induced prolongation of repolarization
depended on both cycle length and drug concentration.
The prolongation was greater with increased cycle
lengths (Figures 2A and B).
In comparison to previous microelectrode studies (36), the absolute change in CL was relatively smaller in the
present model. For example, Tande et al. (3) performed
stimulation at a CL of 500 ms up to 2000 ms to assess
rate-dependent prolongation of action potential duration
with a wide range. In contrast, we used faster pacing
rates depending on the presence of spontaneous
sinoatrial nodal activity. Although the maximal change in
CL was only 100 ms, it was possible to show the reverserate- dependent changes in repolarization duration in the
presented model. Thus, the data obtained here by
monophasic action potential recording may confirm that
dofetilide causes in-vitro reverse- or negative-ratedependent prolongation of repolarization (3-6).
On the other hand, we have limited the increase in
drug concentration with 10 nM. It was found that a high
dosage of dofetilide, being 0.1 µM, caused second degree
A-V blocks in isolated rabbit heart, if the CL was
shortened by atrial pacing, but no proarrhythmic activity
such as extrasystol or ventricular tachycardia was seen
due to 0.1 µM dofetilide (un-published data). AV
conduction was affected by the high dosage of dofetilide
in both the closed-chest dog model of Satoh et al. (24)
and the in-vivo rabbit experiments of Lu et al. (25). The
increased concentration dofetilide also induces
polymorphic ventricular tachycardia as well as ventricular
fibrillation (25).

In healthy volunteers, dofetilide caused prolongation
of the QT interval in a reverse- rate- dependent manner
(11,12). In contrast, dofetilide did not produce ratedependent changes in the prolongation of the QT interval
in patients with ischemic heart disease (9). It was also
reported that dofetilide did not induce reverse- ratedependent prolongation of monophasic action potentials
in patients with ventricular tachycardia (10).
The present study is limited as it is an in-vitro model
and does not simulate heart disease. The main purpose of
this study was to investigate not only rate-dependent
prolongation but also rate-dependent changes in
repolarization dispersion inducing faster heart rates.
The drug-induced increase in dispersion of ventricular
repolarization may heighten the risk of ventricular
proarrhythmia (15,16). Therefore, the antiarrhythmic
efficacy of the drug is probably decreased (15,16). The
effects of dofetilide on the dispersion of repolarization
were assessed in patients (9,10), healthy subjects (11)
and in-vivo animal models (8,17). Gwilt et al. (17) have
reported that dofetilide reduced the pacing- induced
heterogeneity of epicardial repolarization in open- chest
dogs. No effect of dofetilide on repolarization dispersion
was determined in humans (9-11) or in post-infarcted
anaesthetized dogs (8). These previous dispersion results
were obtained using monophasic action potential
recording from the right ventricular endocardium (10) or
using surface ECG recordings for QT interval
measurement (8,9,11,17).
In the present in-vitro model, the interventricular
dispersion seems to be increased by relatively higher
dosages, but this dose- dependent increase was not
significant. Obviously, changes in dispersion did not
depend on heart rate (p < 0.05). Thus, stable dispersion
in different heart rates might explain the fact that the
dofetilide does not cause proarrhythmia in isolated rabbit
hearts.
Gillis et al. (18,20) and D’Alonzo et al. (19) have
measured some effects of dofetilide using in-vitro rabbit
hearts. In all of these studies (18-20), no measurement
related to the rate- dependent repolarization changes
induced by dofetilide was obtained. Dofetilide prolonged
monophasic action potential duration in both sham and
hypertrophied hearts at a concentration of 15 nM (18).
Dofetilide was also tested in a drug combination with 4aminopyridine (20). This combination enhanced the
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dispersion of the repolarization in isolated rabbit hearts.
The increase in dispersion was greater in a hypertrophied
heart than the increase of dispersion in a nonhypertrophied one (20). This enhanced dispersion (20)
may induce ventricular fibrillation in an isolated rabbit
heart. The ventricular fibrillation in an isolated rabbit
heart (20) may also be related to ventricular hypertrophy
and/or drug combinations including 4-aminopyridine,
because neither ventricular proarrhythmic activity nor
afterdepolarization was seen in the present model even at
perfusion of 0.1 µM dofetilide (unpublished data).
Similarly, D’Alonzo et al. (19) found that dofetilide, at
concentrations from 0.1 µM to 0.5 µM, did not induce
proarrhythmia in isolated spontaneously beating rabbit
hearts. However, if the acetylcholine and/or the
methoxamine was combined with dofetilide, early
afterdepolarization and/or torsade de pointes was
induced in their model (19).
Dofetilide was found to be an effective and safe
antiarrhythmic in the treatments of atrial fibrillation and
atrial fatter (26-28). There was a small risk (3 %) of
proarrhythmic activity in patients with atrial fibrillation or
with flutter (26). It is likely that dofetilide affects the
ventricular repolarization of the heart by supraventricular
arrhythmia unless inducing proarrhythmia (26). It was
considered that class III antiarrhythmic agents possess
less proarrhythmic activity in fast beating hearts (13). On
the other hand, dofetilide elevated the incidence of
torsade de pointes with enhanced interventricular
dispersion of monophasic action potential (MAPD) in a
novel dog model (22), which is discussed below.
It was reported that the interventricular difference in
MAPD showed very strong bradycardia dependence and it
was much larger than intraventricular dispersion under
ventricular pacing in a dog model with A-V ablation (21).
Moreover, the interventricular dispersion may be more
important than intraventricular dispersion for induction

of torsade de pointes (21). Van Opstal et al. (22) have
used a similar dog model and they have examined the
dofetilide-induced rate-dependency of repolarization
prolongation and of dispersion. It was demonstrated that
a dofetilide-induced increase in the interventricular
dispersion of endocardial repolarization elevated the
incidence of torsade de pointes (22).
In our opinion, the pacing side should be considered
an important factor for the evaluation of drug-induced
repolarization changes and for the induction of
arrhythmias, because an intact heart with atrial pacing
may show a different epicardial repolarization dispersion
in comparison to that with ventricular pacing (14). The
atrial pacing was applied here to assess the in-vitro effect
of dofetilide on the dispersion of repolarization in fast
heart rates, in the absence of A-V ablation and ventricular
pacing. Depending on our experimental procedure, the
presented results are not directly comparable to those of
the dog model mentioned (22).

Conclusion
Dofetilide causes reverse-rate-dependent prolongation
of repolarization duration in atrial- paced isolated rabbit
hearts. Parallel to this finding, the dispersion of
repolarization was stable in different heart rates and no
proarrhythmia was seen. Therefore, the dofetilideinduced repolarization prolongation in the presented
model might indicate a safely antiarrhythmic efficacy in
fast beating hearts driven from the atrium.
Correspondence autor:
Mustafa ÖZBEK
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